menu search

LRMR / Larimar: Friedreich's Ataxia Drug With Significant Potential

Larimar: Friedreich's Ataxia Drug With Significant Potential
Clearance given by FDA to initiate higher 50 mg dosing of CTI-1601 for patients with Friedreich's Ataxia for phase 2 study; results from this cohort expected 1st half of 2024. Clearance given to initiate open-label extension study of CTI-1601 for Friedreich's Ataxia; study initiation Q1 of 2024 and then interim results Q4 of 2024. Prior phase 1 study, using CTI-1601 for the treatment of patients with Friedreich's Ataxia, showed that the drug was able to increase frataxin levels in a dose-dependent manner. Read More
Posted: Aug 2 2023, 06:02
Author Name: Seeking Alpha
Views: 080528

LRMR News  

Larimar: Friedreich's Ataxia Drug With Significant Potential

By Seeking Alpha
August 2, 2023

Larimar: Friedreich's Ataxia Drug With Significant Potential

Clearance given by FDA to initiate higher 50 mg dosing of CTI-1601 for patients with Friedreich's Ataxia for phase 2 study; results from this cohort e more_horizontal

Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?

By Zacks Investment Research
May 9, 2023

Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?

Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). more_horizontal

New Strong Buy Stocks for April 19th

By Zacks Investment Research
April 19, 2023

New Strong Buy Stocks for April 19th

SIGA, RYI, LRMR, VRTV and PLL have been added to the Zacks Rank #1 (Strong Buy) List on April 19, 2023. more_horizontal

Here's Why You Should Invest in Larimar (LRMR) Stock Now

By Zacks Investment Research
April 12, 2023

Here's Why You Should Invest in Larimar (LRMR) Stock Now

Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea. more_horizontal

Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

By GlobeNewsWire
November 21, 2022

Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company more_horizontal


Search within

Pages Search Results: